Stockscreener 앱 받기
5.87
2.17%
-0.13
Clearmind Medicine Inc 주식(CMND)의 최신 뉴스
Psyence Biomedical Ltd. (PBM) Stock Price, News, Quote & History - Yahoo! Finance Canada
SciSparc Ltd. (SPRC) stock price, news, quote and history - Yahoo Finance UK
SciSparc Ltd. (SPRC) Stock Price, News, Quote & History - Yahoo! Finance Canada
SciSparc Ltd. (SPRC) stock price, news, quote and history - Yahoo Finance Singapore
Clearmind Medicine (CMND) Slips 2.49% to $6.26, Pivoting Inside a Tight $5.95–$6.57 BandComposite Profile - https://www.dars.gov.et/
Sagimet Biosciences Inc. (SGMT) stock price, news, quote and history - Yahoo Finance Singapore
Clearmind Medicine Company Profile & Introduction - Moomoo
Net loss narrows to $6.05M, but SciSparc (SPRC) raises substantial doubt about continuing operations. - Stock Titan
OneMedNet Corporation Announces 1-for-10 Reverse Stock Split - Yahoo Finance
Three patent applications pair LSD, ketamine and ibogaine with a proprietary compound. - Stock Titan
Stickit Technologies Announces Corporate Update: Leadership Appointments, Capital Restructuring & Loan Acquisition, And Update Of Intellectual Property Portfolio - TradingView
Clearmind enrolls first AUD patients in CMND-100 trial - grafa.com
Clearmind Enrolls First Patients with Alcohol Use Disorder in CMND-100 Clinical Trial - The Manila Times
Two patients become the first to receive Clearmind's potential treatment for alcohol use disorder. - stocktitan.net
Proposed Nasdaq threshold could threaten Clearmind (NASDAQ: CMND) listing - Stock Titan
Clearmind Medicine(CMND) Stock Options Chain | Quotes & News - Moomoo
Charging Robotics Inc. Sells Majority Stake in Charging Israel to Clearmind Medicine for $2.5M (OTC: CHEV) - Kalkine Media
Clearmind Medicine Announces Yale IRB Approval to Begin Patient Recruitment for CMND-100 Phase I/II Trial in Alcohol Use Disorder - Quiver Quantitative
Clearmind Medicine Receives Yale IRB Approval, Enabling Patient Recruitment for Parts B and C of CMND-100 Phase I/II Trial, Following Positive Safety Results - The Manila Times
Clearmind Medicine Receives Yale IRB Approval, Enabling Patient Recruitment for Parts B and C of CMND-100 Phase I/II Trial, Following Positive Safety Results - marketscreener.com
All 24 trial participants completed treatment with no serious adverse events. Yale can now recruit. - Stock Titan
Clearmind to acquire 51% stake in EV charging firm for $2.5M By Investing.com - Investing.com Australia
Clearmind Medicine to Acquire Majority Stake in Charging Robotics for $2.5 Million - marketscreener.com
CMND Stock Slides As Clearmind Medicine Tightens Cash Belt - StocksToTrade
Clearmind to acquire 51% stake in EV charging firm for $2.5M By Investing.com - Investing.com South Africa
Clearmind Tumbles on Buying into Charging Robotics - Baystreet.ca
Clearmind Medicine Agrees to Acquire 51% Stake in Charging Robotics for $2.5 Million - Yahoo Finance
Clearmind Medicine Stock Slides Friday: What's Happening? - Benzinga
CMND Stock Slides As Traders Eye Key Support Levels - timothysykes.com
Clearmind Medicine Signs Definitive Agreement to Acquire 51% Stake in Wireless Charging Company for Automated Parking and Robotaxis - The Manila Times
CMND Stock Pops As Clearmind Advances AUD Drug To Phase IIa - timothysykes.com
Clearmind to acquire 51% stake in EV charging firm for $2.5M - Investing.com UK
Clearmind Medicine Inc. (CMND) moves into EV wireless charging with a controlling deal - Stock Titan
Clearmind Medicine ลงนามในข้อตกลงขั้นสุดท้ายเพื่อเข้าซื้อหุ้น 51% ในบริษัทระบบชาร์จไร้สายสำหรับระบบจอดรถอัตโนมัติและรถแท็กซี่ไร้คนขับ (Robotaxis) - Moomoo
A biotech plans to buy most of a wireless charging company for robotaxis - Stock Titan
Clearmind Tumbles on Buying into Charging Robotics - Baystreet.ca
Debt-for-share swap at $1 sets new floor at Clearmind (CMND) - Stock Titan
Clearmind Medicine Inc. (CMND) Stock: Jumps Nearly 10% as Phase IIa AUD Trial Begins - Blockonomi
Clearmind starts Phase IIa AUD trial of CMND-100 - Stock Titan
Clearmind Reaches Key Milestone: CMND-100 Phase IIa now Underway for Alcohol Use Disorder Trial, One-Third of Part C Enrolled - The Manila Times
Clearmind Medicine Announces Initiation of Phase IIa Trial for CMND-100 in Alcohol Use Disorder - Quiver Quantitative
Weekly Roundup on the Cannabis Sector & Psychedelic Sector - marketexclusive.com
Clearmind Medicine (CMND) Slips 2.76% to $1.76, Holds Above Key Support at $1.67Hedge Fund Favorites - siam.in
SciSparc: NeuroThera-Clearmind Collaboration Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation - The Manila Times
NeuroThera-Clearmind Collaboration Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation - NewMediaWire
SciSparc: NeuroThera-Clearmind Collaboration Advances - GlobeNewswire
Clearmind (CMND) Market: Adds 0.87% to Close at $1.74; Chart Watch: Support at $1.65 and Resistance at $1.83 Frame the Range in the Latest SessionVolume Rate Change - vinanet.vn
Clearmind (CMND) Market: Adds 0.87% to Close at $1.74; Chart Watch: Support at $1.65 and Resistance at $1.83 Frame the Range in the Latest SessionADD Alert - dars.gov.et
Clearmind (CMND) Market: Adds 0.87% to Close at $1.74; Chart Watch: Support at $1.65 and Resistance at $1.83 Frame the Range in the Latest SessionATR Trailing Stop - dars.gov.et
Clearmind (CMND) Market: Adds 0.87% to Close at $1.74; Chart Watch: Support at $1.65 and Resistance at $1.83 Frame the Range in the Latest SessionFast Moving Stocks - https://www.dars.gov.et/
3.09%
0.72%
자본화:
|
볼륨(24시간):